Emerging therapeutic strategies: The potential of caffeic acid-vanadium nanozymes in modulating macrophage function and reducing skin flap ischemia–reperfusion injury

Autologous skin flap transplantation is a critical technique for repairing complex soft tissue defects resulting from trauma, cancer, and congenital malformations¹. However, ischemia-reperfusion injury (I/R) frequently leads to distal necrosis and functional loss of the flap, severely compromising surgical outcomes. Recently, in Acta Pharm. Sin. B, Wang et al. developed caffeic acid-vanadium metal polyphenol nanoparticles (CA-V NPs), which have shown remarkable efficacy in treating flap I/R injury². These CA-V NPs exhibited enzyme-like activities similar to superoxide dismutase (SOD) and catalase (CAT), enabling the scavenging of reactive oxygen species (ROS) and the production of oxygen. This dual action alleviates oxidative stress and inflammatory responses, significantly reducing I/R-induced damage and enhancing flap survival rates.

The advantages of this study are reflected in the following points: (1) Multi-perspective validation: the anti-oxidative stress and anti-inflammatory effects of CA-V NPs were comprehensively validated by cellular experiments, genome sequencing, and animal models, with reliable results and well-supported data. (2) Highly innovative: As a multifunctional nanoenzyme, CA-V NPs have gained applications in tumors, diabetes, and other diseases, but the research in skin flap I/R injury is still in the exploratory stage, which is highly innovative. (3) Clear mechanism: This study found that CA-V NPs exerted antioxidant and anti-inflammatory effects by regulating multiple signaling pathways such as NF-κB, JAK-STAT, TNF-α, and IL-17 through transcriptome sequencing.

However, several limitations exist in this study: (1) Inadequate assessment of long-term safety: While the article emphasizes the antioxidant and anti-inflammatory effects of CA-V NPs, there is limited discussion regarding potential long-term side effects, such as metal ion accumulation, chronic toxicity, and immune responses. A more detailed safety evaluation is still required. (2) Absence of a control group: The study did not include a control group with other antioxidant materials (e.g., traditional SOD or CAT), which prevents direct comparison with existing treatments and limits the relative assessment of efficacy. (3) Suboptimal drug delivery system: In the in vivo experiments, CA-V NPs were directly injected into the skin flap area. However, subcutaneous injection may not be ideal, as it may not achieve optimal drug efficacy due to the balance between drug activity and metabolism, and the injected solution is prone to leakage, affecting controlled drug release. (4) Clinical feasibility remains to be verified: While significant results were observed in animal experiments, the safety and efficacy of CA-V NPs in humans require further verification. Given the physiological differences between mice and humans, additional studies using non-human primates or patient samples are necessary.

To further promote the clinical translation of this promising therapy, the following directions should be considered for future research: (1) Selection of appropriate formulation: Hydrogel carriers are recommended due to their excellent biocompatibility and three-dimensional structure, which can mimic the extracellular matrix and promote tissue regeneration. Currently, hydrogel matrices such as hyaluronic acid, alginate, and gelatin have been FDA-approved, which can be candidates for the incorporation of CA-V NPs. These hydrogel carriers improve drug retention time at the transplantation site and interact with the polyphenolic structure of caffeic acid to facilitate controlled drug release; (2) Comprehensive safety evaluation: To ensure the safe clinical application of CA-V NPs, future studies should conduct comprehensive assessments of long-term toxicity, immunogenicity, and in vivo behavior. These investigations are essential to confirm the long-term efficacy and identify potential side effects of the therapy; (3) Combination therapy: Metal polyphenol nanoparticles, as drug carriers, can effectively deliver small molecules, proteins, or gene therapies (e.g., curcumin³, luteolin⁴, melatonin⁵). Future studies should explore their potential for combination therapy with existing treatments to enhance efficacy and minimize side effects; (4) Precision medicine applications: The therapeutic precision of CA-V NPs can be enhanced through targeted drug delivery systems or gene editing technologies. For instance, surface modifications (e.g., ligand labeling or surface charge alterations) can improve targeting to the flap transplantation site, or biomimetic membrane-encapsulated metal polyphenol nanoparticles could be used to achieve more precise targeted therapy.

In summary, caffeic acid vanadium metal polyphenol nanoparticles have a promising application in the treatment of skin flap I/R, especially in alleviating oxidative stress, attenuating inflammatory responses, and promoting cell survival, which demonstrated significant potential. With further preclinical studies and clinical validation, CA-V NPs are expected to become an emerging therapy for the treatment of I/R injuries after skin flap transplantation and provide new therapeutic options for other diseases related to oxidative stress and inflammation.